← Back to events
ActiveBusiness

Eli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion

What happened

Lilly will pay $100 million upfront to work with the Beijing-based biotech on as many as five undisclosed drug targets

Summary assembled by rule from the sources below

Sources